Osteoporosis International

, Volume 3, Supplement 3, pp 29–39 | Cite as

Design of the Fracture Intervention Trial

  • D. M. Black
  • T. R Reiss
  • M. C. Nevitt
  • J. Cauley
  • D. Karpf
  • S. R. Cummings
  • the Fracture Intervention Trial Research Group


The Fracture Intervention Trial (FIT) is a randomized, double-masked, placebo-controlled trial designed to test the hypothesis that alendronate, an amino-bisphosphonate, will reduce the rate of fractures in women aged 55–80 years with low hip bone marrow density (<0.68 gm/cm2 at the femoral neck). It is being conducted at 11 clinical centers around the United States with a coordinating center at UC San Francisco. The goal was to randomize 6000 women. When recruitment was completed (in May 1993), 6457 women had been randomized, amounting to 108% of goal. The women were assigned to one of two substudies. The first (Vertebral Deformity study) includes 2023 women who have at least one vertebral deformity, and will test the hypothesis that alendronate reduces the rate of new vertebral deformities during 3 years of follow-up. This substudy has a power of 0.90 to detect a 32% reduction in the incidence of new vertebral deformities, assuming a 6.5% annual incidence of new vertebral deformities in the placebo group. The second study (Clinical Fracture study) includes 4434 women without vertebral deformities at baseline and will test the hypothesis that alendronate reduces the rate of clinically recognized fractures of all types over an average of 4.25 years of follow-up. This substudy has a 0.90 power to detect a 25% reduction in the rate of all clinical fractures, assuming 4% annual incidence in the placebo group. To our knowledge, this is the largest prospective, randomized, controlled study undertaken to determine the effectiveness of a treatment in reducing the risk of fractures in postmenopausal women.


Alendronate Clinical trial Osteoporosis Vertebral fracture 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ross P, Davis J, Vagel J, Wasnich R. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int 1990;46:149–61.Google Scholar
  2. 2.
    Black D, Cummings S, Melton L III. Appendicular bone mineral and a woman's lifetime risk of hip fracture. J Bone Miner Res 1992;7:639–46.Google Scholar
  3. 3.
    Cummings S, Black D, Nevitt M, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72–5.Google Scholar
  4. 4.
    Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802–9.Google Scholar
  5. 5.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PG, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–9.Google Scholar
  6. 6.
    Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319–24.Google Scholar
  7. 7.
    Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med, 1987;317:1169–74.Google Scholar
  8. 8.
    Grady D, Rubin S, Petitti D, Fox C, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37.Google Scholar
  9. 9.
    Chapuy M, Arlot M, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637–42.Google Scholar
  10. 10.
    Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1982;305:556–61.Google Scholar
  11. 11.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sorenson OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71.Google Scholar
  12. 12.
    Cummings SR, Block G, McHenry K, and Baron RB. Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol 1987;126:796–802.Google Scholar
  13. 13.
    Riggs BL and Melton LJ III. Involutional osteoporosis. N Engl J Med 1986;314:1676–84.Google Scholar
  14. 14.
    Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, et al. Appendicular bone density and age predict hip fracture in women. JAMA 1990;263:665–8.Google Scholar
  15. 15.
    Seeley D, Browner W, Nevitt M, Genant H, Scott J, Cummings S. Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med 1991;115:837–42.Google Scholar
  16. 16.
    Ettinger B, Block JE, Smith R, Cummings SR, Harris ST, Genant HK. An examination of the association between vertebral deformities, physical disabilities and psycho-social problems. Maturitas 1988;8:283–96.Google Scholar
  17. 17.
    Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919–23.Google Scholar
  18. 18.
    Black D, Cummings S, Genant H, Nevitt M, Palermo L, Browner W. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992;7:633–8.Google Scholar
  19. 19.
    Mazess RB, Barden H, Ettinger M, Schultz E, Bone density of the radius, spine, and proximal femur in osteoporosis. J Bone Miner Res 1988;3:13–8.Google Scholar
  20. 20.
    Melton LJ, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol 1989;129:1000–11.Google Scholar
  21. 21.
    Black DM, Cummings SR, Stone K, Hudes E, Palermo L, Steiger P. A new approach to defining normal vertebral dimensions. J Bone Miner Res 1991;8:883–92.Google Scholar
  22. 22.
    Friedman LM, Furberg CD, DeMets DL, Fundamentals of clinical trials. 2nd ed. St. Louis, MO: Mosby Year Book, 1985:302.Google Scholar
  23. 23.
    Lan KKG and DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659–63.Google Scholar
  24. 24.
    Casagrande JT, Pike MC, Smith PG. The power function of the ‘exact’ test for comparing two binomial proportions. Appl Statistics 1978;27:176–81.Google Scholar
  25. 25.
    Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, Loss to follow-up, noncompliance and stratification. Biometrics 1986;42:507–19.Google Scholar

Copyright information

© European Foundation for Osteoporosis 1993

Authors and Affiliations

  • D. M. Black
    • 1
  • T. R Reiss
    • 2
  • M. C. Nevitt
    • 1
  • J. Cauley
    • 3
  • D. Karpf
    • 2
  • S. R. Cummings
    • 1
    • 4
  • the Fracture Intervention Trial Research Group
  1. 1.Division of Clinical Epidemiology, Department of Epidemiology and BiostatisticsUniversity of CaliforniaSan Francisco
  2. 2.Merck Research LaboratoriesUSA
  3. 3.Department of Epidemiology, Graduate School of Public HealthUniversity of Pittsburgh
  4. 4.Division of General Internal Medicine, Department of MedicineUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations